Status:
RECRUITING
Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease
Lead Sponsor:
The University of Texas Medical Branch, Galveston
Conditions:
Post Operative Pulmonary Complications
Neuromuscular Blockade
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
The purpose of the study is to determine which combination of neuromuscular blocking agent and reversal agent is safer to use during anesthesia for patients with chronic kidney disease. The main quest...
Detailed Description
Participants will be randomized into one of the two groups (Group 1-Given rocuronium and sugammadex as part of one of the standard regimens of neuromuscular blockade and reversal or Group 2-Given cisa...
Eligibility Criteria
Inclusion
- The subject is able and willing to provide and sign informed consent
- The subject must be between 18 and 80 years of age
- The subject should have chronic kidney disease as defined by glomerular filtration rate
- The surgery must require general anesthesia with endotracheal intubation and neuromuscular blockade
Exclusion
- Any patient under the age of 18
- Any patient over the age of 80
- Any patient with end stage renal disease
- Any patient requiring dialysis
- Patients presenting for Renal Transplantation
- Pregnant Female
- Any patient in the correctional system
- Urgent or Emergent procedure
- The surgery requires intubation post-operatively
- Documented allergy to Rocuronium, Sugammadex, Cisatracurium or Neostigmine
Key Trial Info
Start Date :
August 26 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 26 2027
Estimated Enrollment :
490 Patients enrolled
Trial Details
Trial ID
NCT07203287
Start Date
August 26 2025
End Date
August 26 2027
Last Update
November 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Texas Medical Branch
Galveston, Texas, United States, 77554